Abstract
Introduction Epidemiological and laboratory research seems to suggest that smoking and perhaps nicotine alone could reduce the severity of COVID-19. Likewise, there is some evidence that inhaled corticosteroids could also reduce its severity, opening the possibility that nicotine and inhaled steroids could be used as treatments.
Methods In this prospective cohort study, we will link English general practice records from the QResearch database to Public Health England’s database of SARS-CoV-2 positive tests, Hospital Episode Statistics, admission to intensive care units, and death from COVID-19 to identify our outcomes: hospitalisation, ICU admission, and death due to COVID. Using Cox regression, we will perform sequential adjustment for potential confounders identified by separate directed acyclic graphs to:
Assess the association between smoking and COVID-19 disease severity, and how that changes on adjustment for smoking-related comorbidity.
More closely characterise the association between smoking and severe COVID-19 disease by assessing whether the association is modified by age (as a proxy of length of smoking), gender, ethnic group, and whether people have asthma or COPD.
Assess for evidence of a dose-response relation between smoking intensity and disease severity, which would help create a case for causality.
Examine the association between former smokers who are using NRT or are vaping and disease severity.
Examine whether pre-existing respiratory disease is associated with severe COVID-19 infection.
Assess whether the association between chronic obstructive pulmonary disease (COPD) and asthma and COVID-19 disease severity is modified by age, gender, ethnicity, and smoking status.
Assess whether the use of inhaled corticosteroids is associated with severity of COVID-19 disease.
To assess whether the association between use of inhaled corticosteroids and severity of COVID-19 disease is modified by the number of other airways medications used (as a proxy for severity of condition) and whether people have asthma or COPD.
Conclusions This representative population sample will, to our knowledge, present the first comprehensive examination of the association between smoking, nicotine use without smoking, respiratory disease, and severity of COVID-19. We will undertake several sensitivity analyses to examine the potential for bias in these associations.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form and declare: no support from any organisation for the submitted work; Dr. Tan reports personal fees from AstraZeneca, personal fees from Duke-NUS, outside the submitted work; Dr. Gould reports grants from Wellcome Trust, during the conduct of the study; Dr. Pavord reports personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Aerocrine, personal fees from Almirall, personal fees from Novartis, personal fees from GlaxoSmithKline, personal fees from Genentech, personal fees from Regeneron, personal fees from Teva, grants and personal fees from Chiesi, grants and personal fees from Sanofi, personal fees from Circassia, personal fees from Knopp, grants from NIHR, outside the submitted work; Dr. Watkinson reports grants from Wellcome, grants from NIHR Biomedical Research Centre, Oxford, grants from University of Oxford Medical Sciences Division, during the conduct of the study; personal fees from Sensyne Health, grants from Sensyne Health, outside the submitted work; Dr. Hippisley-Cox reports grants from National Institute for Health Research Biomedical Research Centre, Oxford, grants from John Fell Oxford University Press Research Fund, grants from Cancer Research UK (CR-UK) grant number C5255/A18085, through the Cancer Research UK Oxford Centre, grants from the Oxford Wellcome Institutional Strategic Support Fund (204826/Z/16/Z), during the conduct of the study; personal fees and other from ClinRisk Ltd, outside the submitted work; and JHC is an unpaid director of QResearch, a not-for-profit organisation which is a partnership between the University of Oxford and EMIS Health who supply the QResearch database used for this work; no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
PA is an NIHR senior investigators and is funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) Obesity, Diet and Lifestyle Theme and National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care Oxford. MG, JH-B, MS are funded by Oxford Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
QResearch committee are evaluating this.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Not applicable
